The phase 2 BRIDGE study is an open-label, single-arm study, designed to evaluate the pharmacokinetics, safety and efficacy of melflufen in combination with dexamethasone in multiple myeloma patients with reduced renal function.
Multiple myeloma commonly results in deteriorating renal function. The phase 2 BRIDGE study intends to demonstrate how melflufen can be used in relapsed refractory multiple myeloma patients with renal impairment.
The study started in Q3 2018 and will include up to 25 patients. The last patient is expected to be enrolled in Q2 2021.